Abstract：
BACKGROUND: Current infectious disease screening recommendations for hidradenitis suppurativa (HS) are adopted from recommendations in chronic plaque psoriasis. No HS-specific guidelines for infectious disease screening prior to immunomodulatory therapy have been developed.
OBJECTIVE: The aim of the study was to establish an expert Delphi consensus of recommendations regarding infectious disease screening prior to systemic immunomodulatory therapy in HS.
METHODS: Participants were identified via recent publications in the field and were sent a questionnaire regarding infectious diseases encountered in the setting of HS, and opinions regarding infectious disease screening prior to various systemic immunomodulatory therapies. All questions were informed by a systematic literature review regarding infections exacerbated or precipitated by immunomodulatory therapy. Questionnaire responses were followed by round-table discussion with a core group of 8 experts followed by a final round of questionnaires resulting in achievement of consensus.
RESULTS: 44 expert HS physicians from 12 countries on 5 continents participated in the development of the expert consensus recommendations. Consensus recommendations include screening for hepatitis B, hepatitis C and tuberculosis in all individuals with HS prior to therapy. All immunomodulatory therapies (biologic and systemic immunosuppressant therapy) should be preceded by infectious disease screening including patient and location-specific considerations for endemic local diseases and high-risk activities and occupations. Clinical assessment has a significant role in determining the need for laboratory screening in the setting of many uncommon or tropical diseases such as leprosy, leishmaniasis and strongyloidiasis.
CONCLUSIONS: The presented consensus recommendations are the first specifically developed for pre-treatment infectious disease screening in HS.
OBJECTIVE: The aim of the study was to establish an expert Delphi consensus of recommendations regarding infectious disease screening prior to systemic immunomodulatory therapy in HS.
METHODS: Participants were identified via recent publications in the field and were sent a questionnaire regarding infectious diseases encountered in the setting of HS, and opinions regarding infectious disease screening prior to various systemic immunomodulatory therapies. All questions were informed by a systematic literature review regarding infections exacerbated or precipitated by immunomodulatory therapy. Questionnaire responses were followed by round-table discussion with a core group of 8 experts followed by a final round of questionnaires resulting in achievement of consensus.
RESULTS: 44 expert HS physicians from 12 countries on 5 continents participated in the development of the expert consensus recommendations. Consensus recommendations include screening for hepatitis B, hepatitis C and tuberculosis in all individuals with HS prior to therapy. All immunomodulatory therapies (biologic and systemic immunosuppressant therapy) should be preceded by infectious disease screening including patient and location-specific considerations for endemic local diseases and high-risk activities and occupations. Clinical assessment has a significant role in determining the need for laboratory screening in the setting of many uncommon or tropical diseases such as leprosy, leishmaniasis and strongyloidiasis.
CONCLUSIONS: The presented consensus recommendations are the first specifically developed for pre-treatment infectious disease screening in HS.
摘要：
背景：目前针对化脓性汗腺炎（HS）的传染病筛查建议是从慢性斑块状银屑病的建议中获得的。在免疫调节治疗之前，尚未开发用于传染病筛查的HS特异性指南。
目的：建立关于HS全身免疫调节治疗前传染病筛查建议的专家德尔菲共识。
方法：通过该领域的最新出版物确定了参与者，并向他们发送了一份关于HS环境中遇到的传染病的调查表，以及关于在各种全身免疫调节疗法之前进行传染病筛查的意见。所有问题均通过有关免疫调节疗法加剧或诱发的感染的系统文献综述获得。问卷答复后，与8名专家组成的核心小组进行了圆桌讨论，随后进行了最后一轮问卷，达成了共识。
结果：来自5大洲12个国家的44名专家HS医师参与了专家共识建议的制定。共识建议包括筛查乙型肝炎，治疗前所有HS患者的丙型肝炎和结核病。在所有免疫调节疗法（生物和全身免疫抑制剂疗法）之前，应进行传染病筛查，包括针对地方性疾病和高风险活动和职业的患者和地点特定考虑。临床评估在确定是否需要在许多罕见或热带疾病如麻风病的背景下进行实验室筛查方面具有重要作用。利什曼病和圆线虫病。
结论：所提出的共识建议是第一个专门为治疗前感染性疾病筛查制定的建议。
目的：建立关于HS全身免疫调节治疗前传染病筛查建议的专家德尔菲共识。
方法：通过该领域的最新出版物确定了参与者，并向他们发送了一份关于HS环境中遇到的传染病的调查表，以及关于在各种全身免疫调节疗法之前进行传染病筛查的意见。所有问题均通过有关免疫调节疗法加剧或诱发的感染的系统文献综述获得。问卷答复后，与8名专家组成的核心小组进行了圆桌讨论，随后进行了最后一轮问卷，达成了共识。
结果：来自5大洲12个国家的44名专家HS医师参与了专家共识建议的制定。共识建议包括筛查乙型肝炎，治疗前所有HS患者的丙型肝炎和结核病。在所有免疫调节疗法（生物和全身免疫抑制剂疗法）之前，应进行传染病筛查，包括针对地方性疾病和高风险活动和职业的患者和地点特定考虑。临床评估在确定是否需要在许多罕见或热带疾病如麻风病的背景下进行实验室筛查方面具有重要作用。利什曼病和圆线虫病。
结论：所提出的共识建议是第一个专门为治疗前感染性疾病筛查制定的建议。
